IP Library › Granted Patent US 11,524,037
Granted Patent B2
US 11,524,037 · App. 16/645,019 · Granted Dec 13, 2022

Bacterial extracellular vesicles

Inventors: Brian Goodman (Jamaica Plain, MA); Baundauna Bose (Cambridge, MA); Christopher J. H. Davitt (Boston, MA)
Assignee: Evelo Biosciences, Inc.
A61K35/74A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,524,037
App. No.
16/645,019
Granted
Dec 13, 2022
Kind
B2
Abstract

Provided herein are methods and compositions related to EVs useful as therapeutic agents.

Claims (13)

1. A pharmaceutical composition formulated as a capsule or tablet for oral administration comprising a) at least 1×10 6 isolated bacterial extracellular vesicles (EVs); and b) a pharmaceutically acceptable carrier, wherein at least 90% of the total EV and bacteria particles in the pharmaceutical composition are EVs, wherein the EVs are from Prevotella or Veillonella bacteria.

2. The pharmaceutical composition of claim 1 , wherein at least 95% of the total EV and bacteria particles in the pharmaceutical composition are EVs.

3. The pharmaceutical composition of claim 1 wherein no more than 1% of the total EV and bacteria particles in the pharmaceutical composition are bacteria.

4. The pharmaceutical composition of claim 1 wherein at least 95% of the total protein in the pharmaceutical composition is present in EVs.

5. The pharmaceutical composition of claim 1 , wherein no more than 1% of the total protein in the pharmaceutical composition is present in bacteria.

6. The pharmaceutical composition of claim 1 wherein at least 95% of the total lipids in the pharmaceutical composition is present in EVs.

7. The pharmaceutical composition of claim 1 wherein no more than 1% 95% of the total lipids in the pharmaceutical composition are is present in bacteria.

8. The pharmaceutical composition of claim 1 , wherein bacteria from which EVs are produced are UV irradiated.

9. The pharmaceutical composition of claim 1 , wherein the composition is free of bacteria.

10. The pharmaceutical composition of claim 1 , comprising at least 5×10 6 isolated bacterial EVs.

11. The pharmaceutical composition of claim 1 , wherein the bacterial EVs are from a single strain of bacteria.

12. The pharmaceutical composition of claim 1 , wherein the EVs are from Prevotella histicola bacteria.

13. The pharmaceutical composition of claim 1 , wherein the EVs are from Veillonella tobetsuensis bacteria or Veillonella parvula bacteria.

Assignments (2)
SECURITY INTEREST Recorded Jul 14, 2023
From: EVELO BIOSCIENCES, INC.
To: HORIZON TECHNOLOGY FINANCE CORPORATION
Reel/Frame 064274/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2022
From: GOODMAN, BRIAN; BOSE, BAUNDAUNA; DAVITT, CHRISTOPHER J. H.
To: EVELO BIOSCIENCES, INC.
Reel/Frame 060371/0731 →
Continuity (3)
Provisional Application 62669151 · May 9, 2018
Provisional Application 62556015 · Sep 8, 2017
Related Publication 20200254028A1 · Aug 13, 2020